Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Other Financing Activities
Financing cash flows not reported separately.
Atrium Therapeutics, Inc.NASDAQ: RNA
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities of $301.51M in Q1 FY2026
Q1 FY2026 other financing activities was $301.51M.
Context
- Other financing activities amounted to 228.7% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 42.57M USD
- Year-over-year change
- —
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.57M | — |
Other Financing Activities vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Other Financing Activities figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.